Elsulfavirine

Drug Profile

Elsulfavirine

Alternative Names: Elpida; elpivirine; R1206; RO 4970335; RO 5011500; VM 1500; VM 1500 LAI; VM 1500 Long acting injectable

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Viriom
  • Class Antivirals; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 23 Mar 2017 Elsulfavirine is available for licensing in (excluding USA) as of 23 Mar 2017. https://www.viriom.com/pipeline
  • 17 Mar 2017 Viriom plans to obtain registration for elsulfavirine long-acting injection in Russia in 2022
  • 17 Mar 2017 Phase-II clinical trials in HIV infections (Prevention) in Russia (PO) before March 2017 (Viriom pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top